Home › Blood Cancers
Blood Cancers clinical trials recruiting in the U.S.
153 studies for Blood Cancers are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX46 studies
- New York City, NY26 studies
- Boston, MA25 studies
- Washington, DC19 studies
- Baltimore, MD18 studies
- Seattle, WA18 studies
- Los Angeles, CA17 studies
- Durham, NC16 studies
- Chicago, IL15 studies
- Philadelphia, PA14 studies
- Atlanta, GA13 studies
- Nashville, TN13 studies
- Edison, NJ13 studies
- Baldwin Park, CA13 studies
- Columbus, OH13 studies
- Milwaukee, WI12 studies
- Detroit, MI12 studies
- Dallas, TX12 studies
- Minneapolis, MN11 studies
- Ann Arbor, MI11 studies
- Birmingham, AL11 studies
- Omaha, NE10 studies
- Cincinnati, OH10 studies
- St. Louis, MO10 studies
- Jacksonville, FL10 studies
- Miami, FL9 studies
- Memphis, TN9 studies
- Denver, CO9 studies
- Cedar Rapids, IA9 studies
- San Francisco, CA8 studies
- Aurora, CO8 studies
- Salt Lake City, UT8 studies
- San Antonio, TX8 studies
- Clifton, NJ8 studies
- Tampa, FL8 studies
- Buffalo, NY7 studies
- Madison, WI7 studies
- Grand Rapids, MI7 studies
- Charlotte, NC7 studies
- Phoenix, AZ7 studies
By state
- Alabama11 studies
- Arizona12 studies
- Arkansas5 studies
- California35 studies
- Colorado14 studies
- Connecticut8 studies
- Delaware3 studies
- District of Columbia7 studies
- Florida28 studies
- Georgia16 studies
- Illinois16 studies
- Indiana9 studies
- Iowa9 studies
- Kansas7 studies
- Kentucky10 studies
- Louisiana6 studies
- Maryland29 studies
- Massachusetts26 studies
- Michigan22 studies
- Minnesota17 studies
- Missouri11 studies
- Nebraska10 studies
- Nevada4 studies
- New Hampshire3 studies
- New Jersey21 studies
- New York29 studies
- North Carolina24 studies
- Ohio22 studies
- Oklahoma8 studies
- Oregon8 studies
- Pennsylvania21 studies
- Rhode Island4 studies
- South Carolina8 studies
- South Dakota5 studies
- Tennessee20 studies
- Texas49 studies
- Utah8 studies
- Virginia11 studies
- Washington20 studies
- West Virginia5 studies
- Wisconsin15 studies
Recently updated studies
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Oct 2, 2026 · NCT05724121Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Oct 2, 2026 · NCT06904066Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT03486873Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069Rutgers University Study of the Genetics of Blood Cancers
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 110 · All sexes · Updated Oct 1, 2026 · NCT07714044Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 1, 2026 · NCT06131801A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06697184A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07572006A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04634552Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
Recruiting
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06910969Genomic Profiling in Cancer Patients
RecruitingObservational study
All ages · All sexes · Updated Sep 24, 2026 · NCT01775072Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06398457Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT04728893Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
RecruitingPhase 3
Ages 18 to 71 · All sexes · Updated Sep 23, 2026 · NCT07504458Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345Wearable Activity Tracking to Curb Hospitalizations
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06587100Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
RecruitingEarly phase 1
Ages 12 to 80 · All sexes · Updated Sep 23, 2026 · NCT04744116Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
RecruitingPhase 1/2Healthy volunteers welcome
Ages 12 to 120 · All sexes · Updated Sep 22, 2026 · NCT05470491Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Sep 21, 2026 · NCT07162038Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07648264Bone Marrow Imaging and Clinical Outcomes Across Hematologic, Oncologic, and Other Relevant Conditions
RecruitingObservational study
All ages · All sexes · Updated Sep 18, 2026 · NCT07743476Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
RecruitingPhase 1/2Healthy volunteers welcome
Ages 12 to 120 · All sexes · Updated Sep 18, 2026 · NCT05327023Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
RecruitingObservational study
All ages · All sexes · Updated Sep 17, 2026 · NCT04242095SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
Recruiting
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT05375643Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
RecruitingPhase 1
Up to age 75 · All sexes · Updated Sep 16, 2026 · NCT06345027From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.